teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 47 Projects Releases Packages Wiki Activity Actions 1.2k

auto-fix: strip 11 broken wiki links

Browse source 
Pipeline auto-fixer: removed [[ ]] brackets from links
that don't resolve to existing claims in the knowledge base.
This commit is contained in:
Teleo Agents 2026-03-31 04:33:46 +00:00
parent 3f51ca87ac
commit 251ceeb1a1
4 changed files with 11 additions and 11 deletions
Show stats Download patch file Download diff file Expand all files Collapse all files

2
domains/health/Big Food companies engineer addictive products by hacking evolutionary reward pathways creating a noncommunicable disease epidemic more deadly than the famines specialization eliminated.md
View file

@ -29,7 +29,7 @@ The four major risk factors behind the highest burden of noncommunicable disease
### Additional Evidence (extend)
*Source: [[2025-06-01-cell-med-glp1-societal-implications-obesity]] | Added: 2026-03-15*
*Source: 2025-06-01-cell-med-glp1-societal-implications-obesity | Added: 2026-03-15*
GLP-1s may function as a pharmacological counter to engineered food addiction. The population-level obesity decline (39.9% to 37.0%) coinciding with 12.4% adult GLP-1 adoption suggests pharmaceutical intervention can partially offset the metabolic consequences of engineered hyperpalatable foods, though this addresses symptoms rather than root causes of the food environment.

2
domains/health/only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control-demonstrating-pharmacological-availability-is-not-the-binding-constraint.md
View file

@ -20,7 +20,7 @@ The JACC study tracking 1999-2023 NHANES data reveals a striking failure mode in
---
### Additional Evidence (extend)
*Source: [[2026-03-30-jacc-cvd-mortality-trends-1999-2023]] | Added: 2026-03-30*
*Source: 2026-03-30-jacc-cvd-mortality-trends-1999-2023 | Added: 2026-03-30*
The population-level outcome of poor blood pressure control manifests as doubled hypertensive disease mortality 2000-2023, with 664,000 deaths in 2023 where hypertension was primary or contributing cause. Middle-aged adults (35-64) showed the most pronounced increases, indicating the treatment failure compounds over working-age years.

14
domains/health/semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss-with-inflammation-as-primary-mediator.md
View file

@ -29,12 +29,12 @@ This has major implications: (1) the drug should benefit patients across the BMI
*Auto-converted by substantive fixer. Review: revert if this evidence doesn't belong here.*
### Additional Evidence (confirm)
*Source: [[2026-03-30-lancet-select-adiposity-independent-cv-outcomes-2025]] | Added: 2026-03-30*
*Source: 2026-03-30-lancet-select-adiposity-independent-cv-outcomes-2025 | Added: 2026-03-30*
SELECT trial prespecified analysis (N=17,604) published in The Lancet November 2025 confirms ~67% of MACE reduction is independent of weight/adiposity changes. Treatment effect was consistent across ALL baseline BMI and waist circumference categories with no evidence of heterogeneity. Time-varying weight loss analysis showed 'no evidence that the treatment effect of semaglutide was mediated by time-varying weight loss.' Only ~33% of benefit explained by early waist circumference reductions. This is stronger evidence than the ESC 2024 abstract because it's a prespecified (not exploratory) analysis from the definitive SELECT publication.
### Additional Evidence (confirm)
*Source: [[2026-03-30-lancet-select-adiposity-independent-cv-outcomes-2025]] | Added: 2026-03-30*
*Source: 2026-03-30-lancet-select-adiposity-independent-cv-outcomes-2025 | Added: 2026-03-30*
ESC 2024 mediation analysis (Colhoun/Lincoff) found hsCRP (inflammation marker) mediated 42.1% of CV benefit while body weight mediated only 19.5%. Joint mediation of all measured metabolic factors was 31.4% (95% CI: -30.1% to 143.6%), leaving ~68.6% of benefit unexplained by adiposity or standard metabolic parameters. The convergence between this analysis (68.6% unexplained) and the Lancet prespecified analysis (67% weight-independent) from independent methodologies strengthens the anti-inflammatory mechanism hypothesis.
@ -44,12 +44,12 @@ ESC 2024 mediation analysis (Colhoun/Lincoff) found hsCRP (inflammation marker)
*Auto-converted by substantive fixer. Review: revert if this evidence doesn't belong here.*
### Additional Evidence (confirm)
*Source: [[2026-03-30-lancet-select-adiposity-independent-cv-outcomes-2025]] | Added: 2026-03-30*
*Source: 2026-03-30-lancet-select-adiposity-independent-cv-outcomes-2025 | Added: 2026-03-30*
SELECT trial prespecified analysis (N=17,604, published Lancet Nov 2025) confirms ~67% of MACE reduction is independent of weight/adiposity changes. Treatment effect was consistent across ALL baseline BMI and waist circumference categories with no evidence of heterogeneity. Time-varying weight loss analysis showed 'no evidence that the treatment effect of semaglutide was mediated by time-varying weight loss.' Only ~33% of benefit explained by early waist circumference reductions. This is stronger evidence than the ESC 2024 abstract because it's a prespecified (not exploratory) analysis from the definitive SELECT publication.
### Additional Evidence (confirm)
*Source: [[2026-03-30-lancet-select-adiposity-independent-cv-outcomes-2025]] | Added: 2026-03-30*
*Source: 2026-03-30-lancet-select-adiposity-independent-cv-outcomes-2025 | Added: 2026-03-30*
ESC 2024 mediation analysis (Colhoun/Lincoff) converges on same conclusion via different methodology: body weight mediates only 19.5% of CV benefit, while hsCRP (inflammation marker) mediates 42.1% - the largest single measured factor. Joint mediation of all measured metabolic/adiposity parameters: 31.4%, leaving ~68.6% pleiotropic/unexplained. The two independent analyses (prespecified SELECT and ESC mediation) both arrive at 67-69% weight-independence through different statistical approaches.
@ -59,19 +59,19 @@ ESC 2024 mediation analysis (Colhoun/Lincoff) converges on same conclusion via d
*Auto-converted by substantive fixer. Review: revert if this evidence doesn't belong here.*
### Additional Evidence (confirm)
*Source: [[2026-03-30-lancet-select-adiposity-independent-cv-outcomes-2025]] | Added: 2026-03-30*
*Source: 2026-03-30-lancet-select-adiposity-independent-cv-outcomes-2025 | Added: 2026-03-30*
SELECT trial prespecified analysis (N=17,604, published Lancet November 2025) confirms semaglutide reduced MACE consistently across ALL baseline BMI and waist circumference categories with no evidence of treatment heterogeneity by adiposity level. Approximately 67% of MACE benefit is independent of adiposity/weight change. This is stronger evidence than the ESC 2024 abstract because it's a prespecified, not exploratory, analysis. The flat treatment effect across weight-change categories directly contradicts the hypothesis that benefit concentrates in patients achieving significant weight loss.
### Additional Evidence (extend)
*Source: [[2026-03-30-lancet-select-adiposity-independent-cv-outcomes-2025]] | Added: 2026-03-30*
*Source: 2026-03-30-lancet-select-adiposity-independent-cv-outcomes-2025 | Added: 2026-03-30*
Complementary ESC 2024 mediation analysis (Colhoun/Lincoff) quantifies specific mediators: body weight mediates only 19.5% of CV benefit, while hsCRP (inflammation) mediates 42.1% — making anti-inflammatory pathways the largest single measured mediator, more than double the contribution of weight loss. Joint mediation of all measured factors accounts for only 31.4% (95% CI: -30.1% to 143.6%), leaving ~68.6% pleiotropic/unexplained. The convergence of two independent analyses (67% and 68.6% weight-independent) strengthens the claim that GLP-1s function primarily as anti-inflammatory cardiovascular drugs.
---
### Additional Evidence (confirm)
*Source: [[2026-03-30-eurheartj-select-mediation-analysis-esc-2024]] | Added: 2026-03-30*
*Source: 2026-03-30-eurheartj-select-mediation-analysis-esc-2024 | Added: 2026-03-30*
ESC 2024 mediation analysis quantifies specific mediator contributions: hsCRP (inflammation) accounts for 42.1% of CV benefit, body weight only 19.5%, waist circumference 64.0%. Joint mediation of ALL measured factors (weight, inflammation, HbA1c, waist) explains only 31.4% (95% CI: -30.1% to 143.6%), leaving ~68.6% unexplained. This confirms the weight-independence finding from the Lancet 2025 prespecified analysis and adds the specific breakdown showing inflammation mediates MORE than weight loss.

4
domains/health/the epidemiological transition marks the shift from material scarcity to social disadvantage as the primary driver of health outcomes in developed nations.md
View file

@ -27,13 +27,13 @@ Since specialization and value form an autocatalytic feedback loop where each am
### Additional Evidence (confirm)
*Source: [[2024-09-19-commonwealth-fund-mirror-mirror-2024]] | Added: 2026-03-12 | Extractor: anthropic/claude-sonnet-4.5*
*Source: 2024-09-19-commonwealth-fund-mirror-mirror-2024 | Added: 2026-03-12 | Extractor: anthropic/claude-sonnet-4.5*
The Commonwealth Fund's 2024 international comparison demonstrates this transition empirically across 10 developed nations. All countries compared (Australia, Canada, France, Germany, Netherlands, New Zealand, Sweden, Switzerland, UK, US) have eliminated material scarcity in healthcare — all possess advanced clinical capabilities and universal or near-universal access infrastructure. Yet health outcomes vary dramatically. The US spends >16% of GDP (highest by far) with worst outcomes, while top performers (Australia, Netherlands) spend the lowest percentage of GDP. The differentiator is not clinical capability (US ranks 2nd in care process quality) but access structures and equity — social determinants. This proves that among developed nations with sufficient material resources, social disadvantage (who gets care, discrimination, equity barriers) drives outcomes more powerfully than clinical quality or spending volume.
### Additional Evidence (extend)
*Source: [[2025-06-01-cell-med-glp1-societal-implications-obesity]] | Added: 2026-03-15*
*Source: 2025-06-01-cell-med-glp1-societal-implications-obesity | Added: 2026-03-15*
GLP-1 access inequality demonstrates the epidemiological transition in action: the intervention addresses metabolic disease (post-transition health problem) but access stratifies by wealth and insurance status (social disadvantage), potentially widening health inequalities even as population-level outcomes improve. The WHO's emphasis on 'multisectoral action' and 'healthier environments' acknowledges that pharmaceutical solutions alone cannot address socially-determined health outcomes.